News about Market

INCOG BioPharma Announces USD 200 Million Expansion

INCOG BioPharma has announced a USD 200 million expansion aimed at significantly increasing its injectable drug product manufacturing capacity, with plans to grow its workforce to nearly 1,000 employees at its Fishers campus by 2030.

Market | 17/12/2025 | By News Bureau |  445

Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma

Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.

Market | 17/12/2025 | By News Bureau |  313

XOMA Royalty to Acquire Generation Bio

The acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna.

Market | 17/12/2025 | By News Bureau |  210

Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline

Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.

Market | 16/12/2025 | By News Bureau |  427

Vor Bio Announces USD 150 Million Private Placement

Vor Bio has announced a private placement expected to raise approximately USD 150 million in gross proceeds before expenses, with the transaction anticipated to close on or about 18 December, 2025, subject to customary closing conditions.

Market | 16/12/2025 | By News Bureau |  211

Adaptive Biotechnologies Signs Two Immune Receptor Licensing Deals with Pfizer

Adaptive Biotechnologies has signed two immune receptor licensing agreements with Pfizer, covering a T-Cell Receptor (TCR) discovery collaboration in rheumatoid arthritis and access to Adaptive’s proprietary TCR-antigen datasets for immunology R&D.

Market | 16/12/2025 | By News Bureau |  294

Dyadic Applied BioSolutions Forms Commercial Partnership for Recombinant Growth Factors and Media Proteins

Dyadic Applied BioSolutions has entered into a commercial partnership with Opes to accelerate adoption of its recombinant growth factors and media proteins, leveraging Opes’ market presence in Europe, Israel and Asia, while retaining Dyadic’s ability to sell directly and engage additional partners, globally.

Market | 16/12/2025 | By News Bureau |  158

ADEL Signs USD 1.04 Billion Global Licensing Deal with Sanofi for Alzheimer's Drug

ADEL has signed a global licensing deal with Sanofi for its investigational Alzheimer’s therapy ADEL-Y01, valued at up to USD 1.04 billion, including a USD 80 million upfront payment, milestone payments and royalties.

Market | 16/12/2025 | By News Bureau |  241

Viva Biotech-Backed Arthrosi Enters USD 1.5 Billion Acquisition Deal with Sobi

Biovitrum AB (Sobi) has entered into an acquisition agreement with Viva Biotech–backed Arthrosi Therapeutics, with a total deal value of up to USD 1.5 billion, including USD 950 million upfront and up to USD 550 million in contingent payments, subject to closing in the first half of 2026.

Market | 16/12/2025 | By News Bureau |  269

Akums Launches Enhanced Gabapentin ER Formulation for PHN

Akums Drugs and Pharmaceutical has introduced an enhanced Gabapentin Extended-Release (ER) formulation powered by its RetenEx technology for the management of postherpetic neuralgia (PHN), a chronic neuropathic pain condition that affects around 10-20 percent of patients following a shingles outbreak.

Market | 15/12/2025 | By News Bureau |  274